• 1
    Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmström PU, Tötterman TH. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007; 177:353358.
  • 2
    O'Donnell MA. Optimizing BCG therapy. Urol Oncol 2009; 27:325328.
  • 3
    Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:23142330.
  • 4
    Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette–Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325:12051209.
  • 5
    Morales A, Ottenhof P, Emerson L. Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette–Guerin. J Urol 1981; 125:649651.
  • 6
    Williams SK, Hoenig DM, Ghavamian R, Soloway M. Intravesical therapy for bladder cancer. Exp Opin Pharmacother 2010; 11:947958.
  • 7
    Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175:20042010.
  • 8
    Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 1979; 62:10171023.
  • 9
    Chen F, Zhang G, Cao Y, Hessner MJ, See WA. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette–Guerin. J Urol 2009; 182:29322937.
  • 10
    Bockholt NA, Knudson MJ, Henning JR et al. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette–Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. J Urol 2012; 187:22282235.
  • 11
    Luo Y, Chen X, O'donnell MA. Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model. J Urol 2004; 172:24142420.
  • 12
    Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmström PU, Tötterman TH. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim 2005; 39:384393.
  • 13
    Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999; 59:911917.
  • 14
    Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63:21502157.
  • 15
    Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007; 61:299305.
  • 16
    Tham SM, Ng KH, Pook SH, Esuvaranathan K, Mahendran R. Tumor and microenvironment modification during progression of murine orthotopic bladder cancer. Clin Dev Immunol 2011; 2011:865684.
  • 17
    Nadler R, Luo Y, Zhao W et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette–Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 2003; 131:206216.
  • 18
    Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette–Guerin treatment for superficial bladder cancer. J Urol 2002; 167:364367.
  • 19
    Riemensberger J, Böhle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002; 127:2026.
  • 20
    Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003; 21:1726.
  • 21
    Luo Y, Chen X, Han R, Chorev M, DeWolf WC, O'Donnell MA. Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma. J Urol 1999; 162:15191526.
  • 22
    Yang AS, Monken CE, Lattime EC. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res 2003; 63:69566961.
  • 23
    Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother 2004; 27:329338.
  • 24
    Fry TJ, Shand JL, Milliron M, Tasian SK, Mackall CL. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother 2009; 58:12571264.